Articles from: HCP Live
In this interview, Siperstein explained some of the biggest takeaways from her conference presentation on advances in microneedling techniques, including radiofrequency...
-
ICYMI: In this #AAD23 interview, Dr. Robyn Siperstein explained some of the biggest takeaways from her conference presentation on advances in #microneedling techniques, including radiofrequency specifically: https://t.co/y8nSA7dY21 - view on twitter
A phase 2 trial comparing once weekly basal insulin Fc against once daily insulin degludec, results of the study will help provide the basis...
-
New research from a phase 2 trial suggests once-weekly basal insulin Fc achieved similar glycemic control as once-daily insulin degludec in patients with #Type2Diabetes: https://t.co/N6YjjcpB4X - view on twitter
Statistical analysis showed no differences between each pairwise comparison of the bevacizumab biosimilars, MB02-SP and MB02-DM, and the reference...
-
The bevacizumab #biosimilars, MB02-SP (Standard Process) and MB02-DM (Defined Media), demonstrated similar pharmacokinetics (PK), safety, immunogenicity, and bioequivalence compared with the reference drug. https://t.co/vsvvQ9JNzX - view on twitter
Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus...
-
#Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic #lupus erythematosus: https://t.co/GxKD0cgs0O - view on twitter
Mashup Score:1
HCP LiveIndustry Payments to Cardiologists Totaled Over $1 Billion From 2014 to 2019 - 17 hours
Mashup Score:1
Industry payments to cardiologists remained highly prevalent in each year of study, but the research showed significant declines in the total value of payments...
-
Cardiologists in the United States received 5.5 million industry payments totaling $1.1 billion from 2014 to 2019, according to new study results. Read more: https://t.co/mDOQs0peqC #cardiology - view on twitter
Mashup Score:1
HCP LiveFDA Approves High-Concentration Formulation Biosimilar Adalimumab-Adaz - 19 hours
Mashup Score:1
The approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of...
-
ICYMI: The FDA approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of #biosimilar adalimumab 50 mg/mL and adalimumab high-concentration formulation. https://t.co/UBfYCpBagR - view on twitter
New data highlighted racial and ethnic differences between patients with Merkel cell carcinoma, indicating that rates for survival were roughly similar but other distinctions...
-
New data highlighted racial & ethnic differences between Merkel cell carcinoma patients, indicating that rates for survival were similar but other distinctions remained. Check out the story here: https://t.co/7la2G7yPKm - view on twitter
In a recent phase 2 trial, abatacept failed to significantly reduce progression to diabetes or abnormal glucose tolerance among a cohort of stage 1...
-
Abatacept missed the mark for its primary endpoint in a recent phase 2 trial for preventing or delaying #Type1Diabetes: https://t.co/38ZYYm3C3F - view on twitter
No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving...
-
No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving #secukinumab: https://t.co/IrsJuZjhBV - view on twitter
A new survey found the COVID-19 pandemic changed many Americans view of obesity and caused others to consider new weight-loss methods due to their...
Approximately 6.4 million Americans considered having weight-loss surgery or using anti- #obesity prescription drugs during the #COVID19 pandemic. Read more: https://t.co/FT1dJBkPfs - view on twitter